Skip to the main content.

Cell and Gene Therapy Series. Part 4 - Managing costs and scale-up risks for medical devices

Dr. Dave Seaward : 28 February 2022

Cell and Gene Therapy Series. Part 4 - Managing costs and scale-up risks for medical devices

As we continue to explore the world of cell and gene therapy, we now take a look at managing costs and scale up risks for medical devices.

Author Dave Seward, discusses how the principles of Quality by Design (QbD) and Design for Manufacture (DfM) can be applicable to ATMPs. Read this blog now!
The Future of Aseptic Manufacturing: Compact and Advanced Solutions

The Future of Aseptic Manufacturing: Compact and Advanced Solutions

David Johnson: 24 November 2025

As the pharmaceutical industry advances into more complex modalities, from biologics to cell and gene therapies, the need for flexible,...

Read More
Putting Annex 1 into Practice: What Small-Batch Manufacturers Need to Know

Putting Annex 1 into Practice: What Small-Batch Manufacturers Need to Know

David Johnson: 24 November 2025

In this webinar recap, David Johnson, Sales & Marketing Director at 3P innovation, and Tracy Moore, Principal Consultant at TM Pharma and former...

Read More
Precision Blister Filling: Ensuring Consistent Dose Delivery in DPIs

Precision Blister Filling: Ensuring Consistent Dose Delivery in DPIs

Tom Bailey: 21 November 2025

Read More